Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs
| Autor: | Dalip J. S. Sirinathsinghji, J. D. Pickard, George McAllister, R. Hopkins, A. J. Butler, Jenny Longmore, David R. Shaw, Raymond G. Hill, Smith David W |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Agonist
Adult Male Serotonin medicine.drug_class Migraine Disorders Molecular Sequence Data Neuropeptide Sensory system Pharmacology medicine Humans Amino Acid Sequence Neurons Afferent Trigeminal Nerve Medulla Aged Aged 80 and over business.industry Meninges General Medicine Middle Aged Immunohistochemistry Sumatriptan medicine.anatomical_structure Cerebrovascular Circulation Female Neurology (clinical) Dura Mater medicine.symptom 5-HT1D receptor business Neuroscience Vasoconstriction medicine.drug Brain Stem |
| Zdroj: | Cephalalgia : an international journal of headache. 17(8) |
| ISSN: | 0333-1024 |
| Popis: | Sumatriptan, a 5HT1B/1D-receptor agonist, is clinically effective as an antimigraine agent. Its therapeutic action may result partly from vasoconstriction of excessively dilated cranial blood vessels (a 5HT1B-receptor mediated response). The antimigraine activity of sumatriptan may also result from inhibition of the release of vasoactive neuropeptides from trigeminal sensory fibres within the meninges. The identity of the 5HT1B/1D-receptor subtype mediating this effect is unknown. Using 5HT1D- and 5HT1B-receptor-specific antibodies we have demonstrated a differential distribution of these receptor subtypes within the human trigemino-cerebrovascular system. Only 5HT1B-receptor protein was detected on dural arteries. In contrast, only 5HT1D-receptor protein was detected on trigeminal sensory neurones including peripheral and central projections to dural blood vessels and to the medulla. Within the medulla 5HT1D-receptor protein was confined to discrete areas associated with the trigeminal sensory system. These findings have important implications for the design of new antimigraine drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text